UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2020-03, Vol.72 (3), p.465-476

2020

Volltextzugriff (PDF)

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis

Annals of the rheumatic diseases, 2018-09, Vol.77 (9), p.1362-1371

2018

Volltextzugriff (PDF)

Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2014-06, Vol.66 (6), p.1625-1635

2014

Volltextzugriff (PDF)

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis

Annals of the rheumatic diseases, 2012-07, Vol.71 (7), p.1235-1242

2012

Volltextzugriff (PDF)

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

Arthritis research & therapy, 2014-02, Vol.16 (1), p.R53-R53, Article R53

2014

Volltextzugriff (PDF)

Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis

Rheumatology (Oxford, England), 2015-11, Vol.54 (11), p.2015-2024

2015

Volltextzugriff (PDF)

Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis

Arthritis & rheumatology (Hoboken, N.J.), 2023-03, Vol.75 (3), p.449-458

2023

Volltextzugriff (PDF)

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis

Annals of the rheumatic diseases, 2021-12, Vol.80 (12), p.1584-1593

2021

Volltextzugriff (PDF)

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Scientific reports, 2022-07, Vol.12 (1), p.11212-11212, Article 11212

2022

Volltextzugriff (PDF)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

Arthritis research & therapy, 2022-06, Vol.24 (1), p.130-130, Article 130

2022

Volltextzugriff (PDF)

Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients

Rheumatology (Oxford, England), 2021-08, Vol.60 (8), p.3945-3946

2021

Volltextzugriff (PDF)

Clinical and serological hallmarks of systemic sclerosis overlap syndromes

Journal of rheumatology, 2011-11, Vol.38 (11), p.2406-2409

2011

Volltextzugriff (PDF)

Dysregulated B cell function and disease pathogenesis in systemic sclerosis

Frontiers in immunology, 2023-01, Vol.13, p.999008

2023

Volltextzugriff (PDF)

Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease

The lancet respiratory medicine, 2020-03, Vol.8 (3), p.226-227

2020

Volltextzugriff (PDF)

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Arthritis research & therapy, 2021-09, Vol.23 (1), p.234-234, Article 234

2021

Volltextzugriff (PDF)

Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis

Clinical reviews in allergy & immunology, 2023-06, Vol.64 (3), p.378-391

2023

Volltextzugriff (PDF)

News and failures from recent treatment trials in systemic sclerosis

European journal of rheumatology, 2020-10, Vol.7 (3), p.242-S248

2020

Volltextzugriff (PDF)

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

Arthritis research & therapy, 2017-07, Vol.19 (1), p.156-156, Article 156

2017

Volltextzugriff (PDF)

Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features

Journal of rheumatology, 2022-05, Vol.49 (5), p.544-546

2022

Volltextzugriff (PDF)

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups

Annals of the rheumatic diseases, 2023-12, Vol.82 (12), p.1568-1579

2023

Volltextzugriff (PDF)

The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review

Clinical reviews in allergy & immunology, 2017-06, Vol.52 (3), p.401-423

2017

Volltextzugriff (PDF)

A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis

Journal of rheumatology, 2023-07, Vol.50 (7), p.907-915

2023

Volltextzugriff (PDF)

BSR and BHPR guideline for the treatment of systemic sclerosis

Rheumatology (Oxford, England), 2016-10, Vol.55 (10), p.1906-1910

2016

Volltextzugriff (PDF)

Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis

Rheumatology (Oxford, England), 2016-01, Vol.55 (1), p.115-119

2016

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Englisch
(148)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(76)
Rheumatology
(58)
Humans
(48)
Systemic Sclerosis
(43)
Scleroderma
(41)
Female
(25)
Male
(25)
Middle Aged
(21)
Adult
(19)
Autoantibodies
(14)
Scleroderma, Systemic - Complications
(14)
Aged
(11)
Biological And Medical Sciences
(10)
Patients
(10)
Retrospective Studies
(10)
Scleroderma, Systemic - Diagnosis
(10)
Scleroderma, Systemic - Immunology
(10)
Severity Of Illness Index
(10)
Fibrosis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis

Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index

Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis

Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis

Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients

Clinical and serological hallmarks of systemic sclerosis overlap syndromes

Dysregulated B cell function and disease pathogenesis in systemic sclerosis

Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis

News and failures from recent treatment trials in systemic sclerosis

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups

The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review

A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis

BSR and BHPR guideline for the treatment of systemic sclerosis

Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis

Suchergebnisse filtern